Nuveen Asset Management LLC Has $560.01 Million Stock Position in HCA Healthcare, Inc. (NYSE:HCA)

Nuveen Asset Management LLC increased its holdings in HCA Healthcare, Inc. (NYSE:HCA) by 4.5% in the 4th quarter, Holdings Channel reports. The fund owned 1,865,771 shares of the company’s stock after purchasing an additional 81,105 shares during the period. Nuveen Asset Management LLC’s holdings in HCA Healthcare were worth $560,011,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. OMERS ADMINISTRATION Corp lifted its stake in HCA Healthcare by 3.3% in the 4th quarter. OMERS ADMINISTRATION Corp now owns 13,067 shares of the company’s stock worth $3,922,000 after acquiring an additional 421 shares in the last quarter. Lazard Asset Management LLC raised its stake in shares of HCA Healthcare by 20.2% during the 4th quarter. Lazard Asset Management LLC now owns 161,715 shares of the company’s stock worth $48,538,000 after purchasing an additional 27,139 shares in the last quarter. LMR Partners LLP purchased a new stake in shares of HCA Healthcare during the 4th quarter worth about $326,000. Janus Henderson Group PLC raised its stake in shares of HCA Healthcare by 14.9% during the 4th quarter. Janus Henderson Group PLC now owns 1,538,826 shares of the company’s stock worth $461,883,000 after purchasing an additional 199,188 shares in the last quarter. Finally, Humankind Investments LLC raised its stake in shares of HCA Healthcare by 15.3% during the 4th quarter. Humankind Investments LLC now owns 4,317 shares of the company’s stock worth $1,296,000 after purchasing an additional 573 shares in the last quarter. 62.73% of the stock is owned by hedge funds and other institutional investors.

HCA Healthcare Price Performance

Shares of NYSE:HCA opened at $366.98 on Thursday. HCA Healthcare, Inc. has a 1-year low of $289.98 and a 1-year high of $417.14. The firm has a market capitalization of $88.29 billion, a PE ratio of 16.70, a PEG ratio of 1.10 and a beta of 1.46. The business’s 50 day moving average is $338.45 and its 200-day moving average is $328.35. The company has a current ratio of 1.08, a quick ratio of 0.97 and a debt-to-equity ratio of 69.07.

HCA Healthcare (NYSE:HCA) last announced its quarterly earnings data on Friday, April 25th. The company reported $6.45 earnings per share for the quarter, topping the consensus estimate of $5.75 by $0.70. HCA Healthcare had a return on equity of 586.47% and a net margin of 8.16%. The company had revenue of $18.32 billion for the quarter, compared to analyst estimates of $18.26 billion. During the same quarter last year, the firm earned $5.36 EPS. HCA Healthcare’s revenue for the quarter was up 5.7% compared to the same quarter last year. Sell-side analysts predict that HCA Healthcare, Inc. will post 24.98 earnings per share for the current year.

HCA Healthcare Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 16th will be given a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 0.78%. The ex-dividend date is Monday, June 16th. HCA Healthcare’s dividend payout ratio (DPR) is 12.81%.

Insiders Place Their Bets

In other HCA Healthcare news, SVP Jennifer Berres sold 9,533 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $322.59, for a total transaction of $3,075,250.47. Following the completion of the transaction, the senior vice president now directly owns 15,412 shares in the company, valued at $4,971,757.08. This represents a 38.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.30% of the company’s stock.

Analyst Upgrades and Downgrades

HCA has been the subject of a number of recent research reports. Royal Bank of Canada cut their price target on HCA Healthcare from $384.00 to $376.00 and set an “outperform” rating for the company in a research note on Monday, April 28th. Barclays cut their price objective on HCA Healthcare from $392.00 to $366.00 and set an “overweight” rating on the stock in a research note on Monday, January 27th. Guggenheim assumed coverage on HCA Healthcare in a research note on Wednesday, April 9th. They issued a “neutral” rating on the stock. Baird R W downgraded HCA Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, April 15th. Finally, StockNews.com raised HCA Healthcare from a “hold” rating to a “buy” rating in a research note on Monday, April 28th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, HCA Healthcare presently has an average rating of “Moderate Buy” and an average target price of $381.13.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.